Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mitralign has closed a $24 million series C financing which will enable the company to complete its initial clinical experience and obtain CE Mark approval of the Mitralign System.
Subscribe to our email newsletter
This round, co-led by Medtronic and Johnson and Johnson Development Corporation, also includes Oakwood Medical, Palisades Capital and Accelerated Technology Partners. Existing investors Forbion, Giza, Oxford Biosciences and Triathlon Medical Venture Partners also participated in the round.
John MacMahon, president & CEO of Mitralign, said: “This financing will allow us to advance our endeavor to emulate surgical precision with a catheter-based approach for mitral valve repair.”